Aprea Therapeutics (APRE) Fundamentals 2026 — Revenue Analysis | SniperIQ
Aprea Therapeutics (APRE) is a US-listed Healthcare company in Biotechnology with a market capitalization of $4M, trading at $0.67 on the NASDAQ. This SniperIQ fundamentals page covers Aprea Therapeutics's valuation, profitability (net margin -10121.7%), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Aprea Therapeutics's market cap?
Aprea Therapeutics (APRE) has a market capitalization of approximately $4M, trading at $0.67 on the NASDAQ. Market cap moves with the live share price.
What is Aprea Therapeutics's P/E ratio?
Aprea Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Aprea Therapeutics?
Aprea Therapeutics runs a net profit margin of -10121.7%, a gross margin of -1523.6%, and an operating margin of -10649.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Aprea Therapeutics pay a dividend?
Aprea Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Aprea Therapeutics financially healthy?
Aprea Therapeutics carries a debt-to-equity ratio of 0.00x and a current ratio of 8.92x, with a market beta of 1.56. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Aprea Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Aprea Therapeutics (APRE) the key facts are: market cap $4M, 52-week range 0.548-2.22. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Aprea Therapeutics's full fundamentals live
Get Aprea Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.